Cytokinetics receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cytokinetics Inc (CYTK)
Cytokinetics Inc stock price live, this page displays NASDAQ CYTK stock exchange data. View the CYTK premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Cytokinetics Inc real time stock price chart below.
What Is the Cytokinetics Inc Stock Price Today?
The Cytokinetics Inc stock price today is 71.40.
What Is the Stock Symbol for Cytokinetics Inc?
The stock ticker symbol for Cytokinetics Inc is CYTK.
Is CYTK the Same as $CYTK?
$CYTK is a common way to refer to the Cytokinetics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Cytokinetics Inc Trade On?
Cytokinetics Inc is listed and trades on the NASDAQ stock exchange.
Is Cytokinetics Inc a Good Stock to Buy?
Determining whether Cytokinetics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Cytokinetics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CYTK quote. (ISIN: US23282W6057)
What Is the Cytokinetics Inc Stock Price Today?
The Cytokinetics Inc stock price today is 71.40.
What Is the Stock Symbol for Cytokinetics Inc?
The stock ticker symbol for Cytokinetics Inc is CYTK.
Is CYTK the Same as $CYTK?
$CYTK is a common way to refer to the Cytokinetics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Cytokinetics Inc Trade On?
Cytokinetics Inc is listed and trades on the NASDAQ stock exchange.
Is Cytokinetics Inc a Good Stock to Buy?
Determining whether Cytokinetics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Cytokinetics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CYTK quote. (ISIN: US23282W6057)
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
69.83
72.46
52 wk Range
47.22
88.31
CYTK is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
69.8372.46
52 wk Range
47.2288.31
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CYTK Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
109.90
Upside
+53.92%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock has taken a big hit over the last week
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Neutral
Moving Averages
Strong Sell
Analyst Ratings
20 Buy
2 Hold
0 Sell
Ratings:
22 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 109.90
(+53.92% Upside)
Cytokinetics Inc SWOT Analysis
Non-Obstructive Expansion | Examine the strategic push into non-obstructive hypertrophic cardiomyopathy, targeting regulatory filing in late 2027 with limited competitive threats |
Analyst Outlook | Average price target stands at $101, with ratings ranging from Overweight to Buy as Wall Street recognizes expanding therapeutic opportunities |
Revenue Trajectory | Peak revenue estimates reach $5.7 billion as analysts project the company will achieve positive EBIT margins by 2029, marking profitability milestone |
Myqorzo's Market Rise | Discover how Cytokinetics' lead cardiovascular drug is capturing physician enthusiasm with projections to command 42% market share by 2030 |
Cytokinetics Inc Earnings Call Summary for Q2/2026
- Cytokinetics beat Q2 2026 estimates with loss of $1.50/share vs. $1.63 expected; revenue hit $28.6M, 67% above $17.09M forecast on MYQORZO strength.
- MYQORZO generated $25.3M in net product revenue; over 1,500 patients dispensed by quarter-end, up from 400 in Q1, with June new-to-brand share topping 40%.
- Company raised 2026 R&D and SG&A expense guidance to $860M-$890M from $830M-$870M to fund nHCM launch prep following positive ACACIA-HCM data.
- Supplemental NDA filing for aficamten in nHCM expected Q4 2026; FDA reviewing MAPLE-HCM sNDA with PDUFA date Nov. 14, 2026 for obstructive HCM indication.
- Cash position strengthened to $1.7B from $1.1B in Q1; European expansion underway with Germany launched, Netherlands approved, U.K. launch expected later 2026.
Last Updated: 08/06/2026, 06:21 PM
Read Full TranscriptEarnings
Latest Release
Aug 06, 2026
EPS / Forecast
-1.50 / -1.63
Revenue / Forecast
28.6M / 17.09M
Compare CYTK to Peers and Sector
Metrics to compare | CYTK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCYTKPeersSector | |
|---|---|---|---|---|
P/E Ratio | −11.1x | −2.3x | −0.4x | |
PEG Ratio | 0.28 | −0.04 | 0.00 | |
Price / Book | −57.2x | −2.2x | 2.6x | |
Price / LTM Sales | 146.7x | 89.4x | 3.1x | |
Upside (Analyst Target) | 49.5% | 286.9% | 49.0% | |
Fair Value Upside | Unlock | 1.4% | 7.0% | Unlock |
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Cytokinetics Inc (CYTK) Stock Price Today?
The Cytokinetics Inc stock price today is 71.40 USD.
What Stock Exchange Does Cytokinetics Inc Trade On?
Cytokinetics Inc is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Cytokinetics Inc?
The stock symbol for Cytokinetics Inc is "CYTK."
What Is the Cytokinetics Inc Market Cap?
As of today, Cytokinetics Inc market cap is 9.93B USD.
What Is Cytokinetics Inc's Earnings Per Share (TTM)?
The Cytokinetics Inc EPS (TTM) is -7.18.
When Is the Next Cytokinetics Inc Earnings Date?
Cytokinetics Inc will release its next earnings report on Oct 29, 2026.
From a Technical Analysis Perspective, Is CYTK a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Cytokinetics Inc Stock Split?
Cytokinetics Inc has split 1 times.
How Many Employees Does Cytokinetics Inc Have?
Cytokinetics Inc has 673 employees.
What is the current trading status of Cytokinetics Inc (CYTK)?
As of Sep 02, 2026, Cytokinetics Inc (CYTK) is trading at a price of 71.40 USD, with a previous close of 71.40 USD. The stock has fluctuated within a day range of 69.83 USD to 72.46 USD, while its 52-week range spans from 47.22 USD to 88.31 USD.
What Is Cytokinetics Inc (CYTK) Price Target According to Analysts?
The average 12-month price target for Cytokinetics Inc is 109.90 USD, with a high estimate of 146 USD and a low estimate of 85 USD. 20 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +53.92% Upside potential.
What Is the CYTK Premarket Price?
CYTK's last pre-market stock price is 71.05 USD. The pre-market share volume is 10,220.00, and the stock has decreased by -0.35, or -0.49%.
What Is the CYTK After Hours Price?
CYTK's last after hours stock price is 70.00 USD, the stock has decreased by -1.40, or -1.96%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.